Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

JACOBIO PHARMACEUTICALS GROUP CO., LTD.
加科思藥業集團有限公司

(Incorporated in the Cayman Islands with limited liability)

(Stock code: 1167)

VOLUNTARY ANNOUNCEMENT
CHANGE IN SHAREHOLDINGS OF THE PARTIES ACTING IN CONCERT AND UPDATES ON ON-MARKET SHARE REPURCHASE BY THE COMPANY

This announcement is made by JACOBIO PHARMACEUTICALS GROUP CO., LTD. (the "**Company**", together with its subsidiaries, the "**Group**") on a voluntary basis to inform the shareholders of the Company (the "**Shareholders**") and potential investors about the progress of repurchase Shares on-market by the Company and the changes in the interests of the parties acting in concert of the Company (the"**Concert Parties**").

I. CHANGE IN SHAREHOLDINGS OF THE PARTIES ACTING IN CONCERT

Reference are made to the announcements of the Company dated July 21, 2025, July 24, 2025, July 30, 2025, and September 4, 2025 in relation to the increase shareholdings of the Concert Parties. The Board (the "**Board**") of directors (the "**Director(s)**") of the Company has been notified by members of the Concert Parties of the Company that, based on their firm confidence in the future development prospects of the Company, from July 16, 2025 up to and including the date of this announcement, they continued to purchase a total of 11,058,650 shares of the Company (the "**Shares**"), involving a total consideration of approximately HK$96.34 million (excluding commissions and other expenses). As of the date of this announcement, the Concert Parties holds a total of 200,157,285 shares of the Company, representing approximately 25.28% of the total issued shares of the Company.

The members of the Concert Parties expressed strong confidence in the Company's overall development prospects, growth potential, and the long-term investment value of its shares. Subject to compliance with applicable laws and regulatory requirements, they do not rule out the possibility of further increasing their shareholdings in the Company at an appropriate time.

II. UPDATES ON ON-MARKET SHARE REPURCHASE

Reference is also made to the announcement of the Company dated July 14, 2025 in relation to the Board's approval of an amount of no more than HK$100 million to repurchase Shares of the Company on-market (the "**Share Repurchase Plan**"). The board believes that the current share price does not reflect the Company's intrinsic value. From July 15, 2025 up to and including the date of this announcement, the Company has repurchased an aggregate of 326,400 shares, for a total consideration of approximately HK$2.67 million. The Company will continue to monitor market conditions and may further exercise the shareholders' mandate to repurchase shares depending on market conditions.

The Board is of the view that the Company's current business operations are in good condition, and the research and development progress of its core product pipeline (including but not limited to the Pan-KRAS inhibitor, etc.) is proceeding smoothly with encouraging data. The substantial shareholding increase by management and the Company's share repurchase action collectively and clearly reflect strong confidence in the Company's fundamentals and long-term growth prospects.

Based on the information available to the Company and to the best of the Board's knowledge, after completion of the shareholding increases and as of the date of this announcement, the Company has conducted in accordance with applicable laws, rules, and regulations, including the Model Code for Securities Transactions by Directors of Listed Issuers set out in Appendix C3 to the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited.

By Order of the Board
JACOBIO PHARMACEUTICALS GROUP CO., LTD.
Yinxiang WANG
Chairman

Hong Kong, September 26, 2025

As at the date of this announcement, the Board comprises Dr. Yinxiang WANG as Chairman and executive Director, Ms. Xiaojie WANG and Ms. Yunyan HU as executive Directors, Dr. Te-li CHEN as non-executive Director, and Dr. Ruilin SONG, Dr. Bai LU and Dr. Ge WU as independent non-executive Directors.